A Phase II Study of Neovii Anti-human T-lymphocyte Immunoglobulin (ATLG, Grafalon®) With Post Transplant Escalated Doses of Post-transplant-Cyclophosphamide to Prevent Acute and Chronic GVHD Post Allogeneic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 16 Sep 2018 Status changed from not yet recruiting to recruiting.
- 17 Apr 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jun 2018.
- 01 Dec 2017 New trial record